Show simple item record

dc.contributor.authorLomax, Anna J
dc.contributor.authorYap, Saw Yee
dc.contributor.authorWhite, Karen
dc.contributor.authorBeith, Jane
dc.contributor.authorAbdi, Ehtesham
dc.contributor.authorBroad, Adam
dc.contributor.authorSewak, Sanjeev
dc.contributor.authorLee, Chooi
dc.contributor.authorSambrook, Philip
dc.contributor.authorPocock, Nicholas
dc.contributor.authorHenry, Margaret J
dc.contributor.authorYeow, Elaine G
dc.contributor.authorBell, Richard
dc.date.accessioned2018-01-11T01:54:00Z
dc.date.available2018-01-11T01:54:00Z
dc.date.issued2013
dc.date.modified2014-06-19T22:43:00Z
dc.identifier.issn2212-1374
dc.identifier.doi10.1016/j.jbo.2013.08.001
dc.identifier.urihttp://hdl.handle.net/10072/60662
dc.description.abstractPostmenopausal women on aromatase inhibitors (AI) are at risk of aromatase inhibitor-associated bone loss (AIBL) and fractures. In 2005 Osteoporosis Australia proposed an algorithm for bisphosphonate intervention. Three hundred and three postmenopausal women with early breast cancer (EBC) were enrolled (osteoporotic, n=25; osteopaenic, n=146; normal bone mineral density (BMD), n=126). Weekly alendronate (70 mg) treatment efficacy as triggered by the algorithm in preventing bone loss was evaluated. All patients received anastrozole (1 mg daily), calcium and vitamin D. Results All osteoporotic patients received alendronate at baseline. Eleven out of the 146 (7.5%) osteopaenic patients commenced alendronate within 18 months of participation and eleven commenced after. One hundred and twenty four out of the 146 (84.9%) osteopaenic patients and all 126 with normal baseline BMD did not trigger the algorithm. At three years, lumbar spine mean BMD increased (15.6%, p<0.01) in the osteoporotic group. BMD in the osteopaenic group with early intervention significantly increased at three years (6.3%, p=0.02). No significant change was seen in the late intervention group. No change was observed in those with osteopaenia without alendronate. There was a significant drop in lumbar spine (-5.4%) and hip (-4.5%) mean BMD, in the normal BMD group, none of whom received alendronate. Fracture data will be presented. Conclusion In postmenopausal women with endocrine-responsive EBC, BMD improved over time when a bisphosphonate is administered with anastrozole in osteoporotic patients using an osteoporosis schedule. Subjects with normal baseline BMD experienced the greatest BMD loss, although none became osteoporotic.
dc.description.peerreviewedYes
dc.description.publicationstatusYes
dc.languageEnglish
dc.publisherElsevier
dc.publisher.placeNetherlands
dc.relation.ispartofstudentpublicationN
dc.relation.ispartofpagefrom145
dc.relation.ispartofpageto153
dc.relation.ispartofissue4
dc.relation.ispartofjournalJournal of Bone Oncology
dc.relation.ispartofvolume2
dc.rights.retentionY
dc.subject.fieldofresearchClinical Sciences not elsewhere classified
dc.subject.fieldofresearchcode110399
dc.titlePrevention of aromatase inhibitor-induced bone loss with alendronate in postmenopausal women: The BATMAN Trial
dc.typeJournal article
dc.type.descriptionC1 - Articles
dc.type.codeC - Journal Articles
dcterms.licensehttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.description.versionPublished
gro.rights.copyright© 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
gro.hasfulltextFull Text
gro.griffith.authorAbdi, Ehtesham


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record